Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma

BACKGROUND: Glioblastoma, the most common primary malignant brain tumor, is nearly universally fatal by 5 years. Dendritic cell vaccines are promising but often limited clinically by antigen choice, dendritic cell potency, and/or manufacturing yield. We optimized vaccine manufacture, generating pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Parney, Ian F, Gustafson, Michael P, Solseth, Mary, Bulur, Peggy, Peterson, Timothy E, Smadbeck, James B, Johnson, Sarah H, Murphy, Stephen J, Vasmatzis, George, Dietz, Allan B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592424/
https://www.ncbi.nlm.nih.gov/pubmed/33134920
http://dx.doi.org/10.1093/noajnl/vdaa105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592424/
https://www.ncbi.nlm.nih.gov/pubmed/33134920
http://dx.doi.org/10.1093/noajnl/vdaa105

Ejemplares similares